A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK),
efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without
dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or
4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.